(Press-News.org) LA JOLLA, CA---Scientists at the Salk Institute for Biological Studies have identified a protein that drives the formation of pituitary tumors in Cushing's disease, a development that may give clinicians a therapeutic target to treat this potentially life-threatening disorder.
The protein, called TR4 (testicular orphan nuclear receptor 4), is one of the human body's 48 nuclear receptors, a class of proteins found in cells that are responsible for sensing hormones and, in response, regulating the expression of specific genes. Using a genome scan, the Salk team discovered that TR4 regulates a gene that produces adrenocorticotropic hormone (ACTH), which is overproduced by pituitary tumors in Cushing's disease (CD). The findings were published in the May 6 early online edition of Proceedings of the National Academy of Sciences.
"We were surprised by the scan, as TR4 and ACTH were not known to be functionally linked," says senior author Ronald M. Evans, a professor in Salk's Gene Expression Laboratory and a lead researcher in the Institute's Helmsley Center for Genomic Medicine. "TR4 is driving the growth and overexpression of ACTH. Targeting this pathway could therapeutically benefit treatment of CD."
In their study, Evans and his colleagues discovered that forced overexpression of TR4 in both human and mouse cells increased production of ACTH, cellular proliferation and tumor invasion rates. All of these events were reversed when TR4 expression was reduced.
First described more than 80 years ago, Cushing's disease is a rare disorder that is caused by pituitary tumors or excess growth of the pituitary gland located at the base of the brain. People with CD have too much ACTH, which stimulates the production and release of cortisol, a hormone that is normally produced during stressful situations.
While these pituitary tumors are almost always benign, they result in excess ACTH and cortisol secretion, which can result in various disabling symptoms, including diabetes, hypertension, osteoporosis, obesity and psychological disturbances. Surgical removal of the tumors is the first-line therapy, with remission rates of approximately 80 percent; however, the disease recurs in up to 25 percent of cases.
Drugs such as cabergoline, which is used to treat certain pituitary tumors, alone or in combination with ketoconazole, a drug normally used to treat fungal infections, have been shown to be effective in some patients with Cushing's disease. More recently, mefipristone-best known as the abortion pill RU-486-was approved by the FDA to treat CD. Despite these advances in medical therapy, the Salk scientists say additional therapeutic approaches are needed for CD.
"Pituitary tumors are extremely difficult to control," says Michael Downes, a senior staff scientist in the Gene Expression Laboratory and a co-author of the study. "To control them, you have to kill cells in the pituitary gland that are proliferating, which could prevent the production of a vital hormone."
Previous studies have found that, by itself, TR4 is a natural target for other signaling molecules in the pituitary. Small-molecule inhibitors that have been developed for other cancers could be potentially applied to disrupt this signaling cascade. "Our discovery," says Evans, a Howard Hughes Medical Institute investigator and holder of the March of Dimes Chair in Molecular and Developmental Biology, "might lead clinicians to an existing drug that could be used to treat Cushing's disease."
INFORMATION:
Other researchers on the study were Li Du, Marvin Bergsneider, Leili Mirsadraei, Stephen H. Young, William H. Yong and Anthony P. Heaney of the David A. Geffen School of Medicine at the University of California, Los Angeles, and Johan W. Jonker of the University of Groningen.
The study was supported by the National Institutes of Health, the Leona M. and Harry B. Helmsley Charitable Trust, the Samuel Waxman Cancer Research Foundation, the Jonsson Comprehensive Cancer Center at UCLA, and Ipsen/Biomeasure.
About the Salk Institute for Biological Studies:
The Salk Institute for Biological Studies is one of the world's preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative, and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer's, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines.
Faculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, M.D., the Institute is an independent nonprofit organization and architectural landmark.
END
DARIEN, IL – A new study suggests that your level of sleepiness or alertness during the day may be related to the type of food that you eat.
Results show that higher fat consumption was associated with increased objective daytime sleepiness, while higher carbohydrate intake was associated with increased alertness. There was no relationship between protein consumption and sleepiness or alertness. These findings were independent of the subjects' gender, age, and body mass index as well as the total amount of sleep they were getting and their total caloric intake.
"Increased ...
DARIEN, IL – A new study suggests that regularity of bedtime prior to initiation of continuous positive airway pressure (CPAP) therapy is an important factor that may influence treatment compliance in adults with obstructive sleep apnea (OSA).
Results show that bedtime variability was a significant predictor of CPAP adherence, which was defined as four or more hours of treatment use per night. The odds of one-month CPAP non-adherence were 3.7 times greater for every one unit increase in habitual, or pre-treatment, bedtime variability.
"Long-term use of CPAP, such as ...
This press release is available in spanish. Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing
### END ...
Boston (May 7, 2013) – The first successful cornea transplant with donor endothelial tissue preloaded by an eye bank has been performed at Massachusetts Eye and Ear in Boston, Mass. Roberto Pineda II, M.D., Director of the Refractive Surgery Service at Mass. Eye and Ear, and an Associate Professor of Ophthalmology at Harvard Medical School, recently performed the groundbreaking transplant.
Dr. Pineda performed the surgery utilizing donor endothelial tissue that was prepared and pre-loaded into EndoGlide™ (Angiotech Pharmaceuticals, Inc.) cartridges at the Lions Eye Institute ...
WASHINGTON, May 7, 2013 – From New York City's Central Park to Golden Gate Park in San Francisco, America's urban forests store an estimated 708 million tons of carbon, an environmental service with an estimated value of $50 billion, according to a recent U.S. Forest Service study.
Annual net carbon uptake by these trees is estimated at 21 million tons and $1.5 billion in economic benefit.
In the study published recently in the journal Environmental Pollution, Dave Nowak, a research forester with the U.S. Forest Service's Northern Research Station, and his colleagues ...
(PHILADELPHIA) An international group of investigators, led by researchers at Thomas Jefferson University's Kimmel Cancer Center, have solved the mystery of why a substantial percentage of castrate-resistant metastatic prostate cancer cells contain abnormally high levels of the pro-growth protein Stat5. They discovered that the gene that makes the protein is amplified — duplicated many times over — in these cancer cells, which allows them to produce excess amounts of the oncogenic protein.
The study, reported in the May 7 issue of the American Journal of Pathology, found ...
Enzymes could break down cell walls faster – leading to less expensive biofuels for transportation – if two enzyme systems are brought together in an industrial setting, new research by the Energy Department's National Renewable Energy Laboratory suggests.
A paper on the breakthrough, "Fungal Cellulases and Complexed Cellulosomal Enzymes Exhibit Synergistic Mechanisms in Cellulose Deconstruction," appears in the current edition of Energy and Environmental Science. Co-authors include five scientists from NREL and one from the Weizmann Institute in Israel.
The Energy ...
Researchers from the U.S. Department of Energy's National Renewable Energy Laboratory (NREL) have quantified the significant value that concentrating solar power (CSP) plants can add to an electric grid.
The NREL researchers evaluated the operational impacts of CSP systems with thermal energy storage within the California electric grid managed by the California Independent System Operator (CAISO). NREL used a commercial production cost model called PLEXOS to help plan system expansion, to evaluate aspects of system reliability, and to estimate fuel cost, emissions, and ...
ANN ARBOR, Mich. — It was a controversial move when a health insurer began requiring people who were obese to literally pay the price of not doing anything about their weight – but it worked, a new study finds.
When people had to choose between paying up to 20 percent more for health insurance or exercising more, the majority of enrollees met fitness goals one step at a time via an Internet-tracked walking program, according to a joint study by the University of Michigan Health System and Stanford University.
Researchers evaluated a group of people insured by Blue ...
A new study shows that pediatric nurse staffing ratios are significantly associated with hospital readmission for children with common medical and surgical conditions.
The study, led by a nurse scientist at Cincinnati Children's Hospital Medical Center, is believed to be the first to examine the extent to which hospital nurse staffing levels are related to pediatric readmissions. Publication of the study comes just weeks after the introduction of federal legislation that would mandate nurse staffing ratios across the country.
The study, published online in the journal ...
